Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression

Xin Li\textsuperscript{a, c, †}, Ye Tian\textsuperscript{b, c, †}, Mei-Juan Tu\textsuperscript{c}, Pui Yan Ho\textsuperscript{c}, Neelu Batra\textsuperscript{c}, Ai-Ming Yu\textsuperscript{a, n}

\textsuperscript{a}Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China
\textsuperscript{b}Lab for Bone Metabolism, Key Lab for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China
\textsuperscript{c}Department of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA

Received 3 October 2018; received in revised form 7 November 2018; accepted 15 November 2018

Abstract Drug-metabolizing enzymes, transporters, and nuclear receptors are essential for the absorption, distribution, metabolism, and excretion (ADME) of drugs and xenobiotics. MicroRNAs participate in the regulation of ADME gene expression via imperfect complementary Watson–Crick base pairings with target transcripts. We have previously reported that Cytochrome P450 3A4 (CYP3A4) and ATP-binding cassette sub-family G member 2 (ABCG2) are regulated by miR-27b-3p and miR-328-3p, respectively. Here we employed our newly established RNA bioengineering technology to produce bioengineered RNA agents (BERA), namely BERA/miR-27b-3p and BERA/miR-328-3p, via fermentation. When introduced into human cells, BERA/miR-27b-3p and BERA/miR-328-3p were selectively processed to target miRNAs and thus knock down CYP3A4 and ABCG2 mRNA and their protein levels, respectively, as compared to cells treated with vehicle or control RNA. Consequently, BERA/miR-27b-3p led to a lower midazolam 1'-hydroxylase activity, indicating the reduction of CYP3A4 activity. Likewise, BERA/miR-328-3p treatment elevated the intracellular accumulation of anticancer drug mitoxantrone, a
1. Introduction

Drug-metabolizing enzymes, transporters, nuclear receptors, and transcription factors are essential for the absorption, distribution, metabolism, and excretion (ADME) of drugs and xenobiotics. Knowledge of the mechanisms involved in expression and function of ADME genes is a prerequisite for predicting drug efficacy and safety profiles, thus it is critical for the practice of personalized or precision medicine. Bioinformatics and experimental studies suggest that miRNAs, a large class of genome-derived, short noncoding RNA (ncRNA) molecules participate in the regulation of ADME gene expression. MiRNAs are capable of inducing translation suppression and/or mRNA cleavage of target genes via imperfect complementary Watson–Crick base pairings with targeted elements that are usually located within the 3′-untranslated regions (3′-UTRs) of target transcripts.

Many miRNAs have been shown to modulate the expression of specific ADME genes (see recent reviews). For instance, miR-27b-3p has been shown to negatively regulate the expression of cytochrome P450s (CYPs) in human carcinoma cells. Previous studies have also demonstrated that miR-27b-3p regulates the expression of CYP3A4, which is the most abundant hepatic and intestinal drug metabolizing enzyme in humans. Changes in CYP3A4 expression and function will undoubtedly lead to a broader variability in drug metabolism as CYP3A4 contributes to the biotransformation of more than 50% of the drugs used in clinic. MiR-27b-3p could also influence other drug metabolizing enzymes and transporters via its regulation to certain nuclear receptors, such as vitamin D receptor (VDR/NR1I1) and retinoid X receptor (RXRα/RXRβ1).

MiR-328-3p and some other miRNAs (e.g., miR-520h, -519c, -328, -181a, and -487a) have been shown to regulate the expression of ABCG2, also known as breast cancer resistance protein (BCRP). ABCG2 is an important transporter in ADME and multidrug resistance (MDR), which plays a critical role in cellular transport of chemotherapeutic drugs such as mitoxantrone, doxorubicin, and topotecan. We have revealed previously that miR-328-3p could regulate ABCG2 expression level and consequently improve the chemosensitivity of ABCG2-overexpressing drug-resistant MCF7/MX100 cells. Further comparative studies have demonstrated that miR-328-3p and -519c are more effective than miR-520h in the regulation of ABCG2 expression in human breast cancer cells. As a result, both miR-328-3p and -519c are able to significantly elevate intracellular accumulation of mitoxantrone, an ABCG2 substrate. These findings suggest that understanding the potential role of miRNAs in epigenetic regulation of ADME genes may offer clues to develop more effective therapeutic strategy, e.g., using miRNAs to combat resistance in chemotherapy.

Nevertheless, currently used RNA interfering (RNAi) miRNA/siRNA materials are limited to the use of viral or non-viral vector-based short hairpin RNA (shRNA) or miRNA expressing systems and chemically engineered miRNA mimics. The shRNA/miRNA expressing vectors, plasmids or other systems are literally DNA-based agents, and the efficiency in targeting relies not only on the effectiveness of gene delivery but also the capability of host cells or organisms to process the DNA into target miRNA/siRNA molecules. On the other hand, chemically engineered RNA mimics carry a wide range of artificial modifications, which is in contrast to natural RNAs produced in live cells that have no or minimal posttranscriptional modifications. Those synthetic RNA agents with extensive artificial modification are undoubtedly to exhibit distinct structures, physicochemical properties, biologic/pharmacological activities, and safety profiles. To produce natural RNA molecules that may better capture the properties of cellular RNAs, we have recently established and further refined a novel tRNA/pre-miRNA-based ncRNA bioengineering technology, which are proven to be useful for the production of many ready-to-use RNAi agents (e.g., miRNAs and siRNAs). These bioengineered RNAi agents (BERA) should represent a new class of RNAi materials for basic and translational research.

In the present study, using BERA/miR-27b-3p and -328-3p as examples, we demonstrated that both BERA/miRNAs were selectively processed to mature miRNAs in human carcinoma cells and thus suppress CYP3A4 and ABCG2 mRNA and their protein levels, respectively, as compared to cells treated with vehicle or control RNA that has been verified as a valid control for assessing the actions of BERAs through various RNA sequencing and functional studies. As a result, BERA/miR-27b-3p led to a lower midazolam 1′-hydroxylase activity suggesting the reduction of CYP3A4-mediated metabolism. Likewise, BERA/miR-328-3p readily facilitated the intracellular accumulation of anticancer drug mitoxantrone, a classic substrate of ABCG2, hence sensitizing the cancer cells to chemotherapy. These findings illustrated the utilities of BERA/miRNA molecules for studying the functions of miRNAs in the regulation of ADME, which may offer clue to the development of improved therapies.

2. Materials and methods

2.1. Chemicals and materials

Midazolam (MDZ) and its metabolite 1′-hydroxymidazolam (1′-OH-MDZ) were purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA) and Cayman Chemical Company (Ann Arbor, MI, USA), respectively. 1′-Hydroxycholecalciferol (1α-VD3) was bought from EMD Millipore (Billerica, MA, USA). Mitoxantrone was bought from Sigma–Aldrich (St. Louis, MO, USA). Fetal bovine serum, RPMI 1640, F-12K medium, trypsin, phosphate-buffered saline (PBS), and antibiotics were bought from...
Invitrogen (Carlsbad, AL, USA). Thiazolyl blue tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), and bovine serum albumin (BSA) were bought from WVR (Radnor, PA, USA). Anti-CYP3A4 antibody and rabbit anti-mouse IgG were purchased from BD Biosciences-Discovery Labware. Anti-GAPDH and anti-VDR antibody were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Peroxidase-conjugated goat anti-rabbit IgG was bought from Jackson ImmunoResearch (West Grove, PA, USA). Primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Chlorozoxazone, 6-hydroxychlorzoxazone, phenacetin and warfarin sodium purchased from Sigma–Aldrich (St. Louis, MO, USA). Acetaminophen was bought from MP Biomedicals, LLC (Solon, OH, USA). Dextromethorphan hydrobromide and dextrophan were purchased from ICN Biomedicals, Inc. (Aurora, OH, USA). Diclofenac sodium was purchased from TCI America (Portland, OR, USA), and 4’-hydroxy diclofenac was from Toronto Research Chemicals, Inc. (Toronto, ON, CA). All other chemicals and organic solvent were purchased from Sigma–Aldrich or Thermo Fisher Scientific Inc. (Waltham, MA, USA).

2.2. Expression and FPLC purification of BERA/miR-27b-3p and BERA/miR-328-3p

The production of BERA/miR-27b-3p, BERA/miR-328-3p, and control RNAs was carried out using the ncRNA bioengineering technology as we described recently. The DNA fragment encoding tRNA/pre-miR-27b-123nt was cloned into the vector pBSMmaSeph linearized by SalI and AatII (New England Biolabs, Ipswich, MA, USA), as described. Likewise, plasmids were constructed to express tRNA/pre-miR-34a (Fig. 1A) based on previously constructed tRNA-hsa-miR-27b-123nt plasmid transformed HST08 (WT) E. coli were used as control, and our previously constructed tRNA-hsa-miR-27b-123nt plasmid transformed HST08 E. coli was utilized for comparison. MiR-27b-3p was expressed at much higher levels when using the tRNA/pre-miR-34a carrier. (C) Representative FPLC traces during the purification of BERA/miR-27b-3p. Inserts were corresponding urea-PAGE analyses of collected fractions (1, 2, 3 and 4) eluted at 8.7 min, which confirmed the purity of isolated recombinant ncRNAs.

recombinant ncRNAs and control RNAs were transfected into the cells within the logarithmic growth phases by using Lipofectamine 3000 reagent, according to the manufacturer’s instructions.

2.4. Reverse transcription quantitative real-time PCR (RT-qPCR)

Cells were treated with recombinant ncRNAs or control RNAs for 48 h. Total RNAs were isolated with Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA), from which the cDNAs were synthesized using NxGen M-MuLV reverse transcriptase (Lucigen, Middleton, WI, USA), with random hexamers or respective stem-loop primers (Supporting Information Table S1). qPCR analyses were carried out using iTaq™ universal SYBR® Green supermix (Bio-Rad, Hercules, CA, USA) and gene-specific primers (Supporting Information Table S1) on a CFX96 Touch real-time PCR system (Bio-Rad, Hercules, CA, USA), as described previously. 18S and GAPDH were used as internal control for the assessment of mRNA levels, and miRNAs were normalized to U74 and U6. Cells were treated in triplicate and assayed separately. The comparative threshold cycle (Ct) method with the formula \(2^{-\Delta\Delta Ct}\) was used to calculate the relative gene expression.

2.5. Western blot analysis

LS-180 cells were treated with 2 μmol/L 1α-VD3 or vehicle for 72 h to induce CYP3A4 expression, and then transfected with BERA/miR-27b-3p or control RNA for 48 h. Cell lysates were prepared for immunoblot analysis using RIPA lysis buffer (Sigma–Aldrich, St.

Figure 1 Bioengineering of new BERA/miR-27b-3p molecule. (A) Schematic illustration of the tRNA/pre-miR-34a carrier used for the production of BERA/miR-27b-3p. (B) Urea-PAGE analysis of total bacterial RNAs showed that chimeric miR-27b-3p was heterogeneously expressed in E. coli using the tRNA/pre-miR-34a scaffold. Total RNAs isolated from untransformed HST08 (WT) E. coli were used as control, and our previously constructed tRNA-hsa-miR-27b-123nt plasmid transformed HST08 E. coli was utilized for comparison. MiR-27b-3p was expressed at much higher levels when using the tRNA/pre-miR-34a carrier. (C) Representative FPLC traces during the purification of BERA/miR-27b-3p. Inserts were corresponding urea-PAGE analyses of collected fractions (1, 2, 3 and 4) eluted at 8.7 min, which confirmed the purity of isolated recombinant ncRNAs.
The samples were analyzed by the LC–MS/MS method, and reconstituted with 100 positive and negative modes respectively. The extracts were evaporated to dryness and reconstituted with 10 nmol/L harmaline and 5 nmol/L warfarin as internal standard for quantification. Cells were maintained at 37 °C overnight. After washing with TBST three times, the resulting membranes were incubated with secondary antibodies conjugated with horseradish peroxidase for 2 h at room temperature. The resultant membranes were washed extensively before analysis. The protein bands were detected by an enhanced chemiluminescence detection system (Bio-Rad), and visualized by a ChemiDoc MP Imaging System (Bio-Rad). ABCG2 expression levels were detected in a similar manner.

2.6. CYPs activity assay

A liquid chromatography–tandem mass spectrometry (LC–MS/MS) cocktail assay was used to determine the cellular activity of five major CYPs in LS-180 cells, as we described previously. Briefly, LS-180 cells were first treated with 2 μmol/L of 1α-VD3 for 72 h, and then transfected with 40 nmol/L BERA/miR-27b-3p or control RNA. At 48 h post-transfection, cocktail substrates (3 μmol/L phenacetin, 2 μmol/L diclofenac, 2 μmol/L dextromethorphan, 3 μmol/L chloroxazone and 1 μmol/L midazolam) were added to the media, and cells were maintained at 37 °C for 90 min. Then 100 μL of media were collected and extracted with 1 mL ethyl acetate containing 10% FBS and 800 nmol/L of mitoxantrone at 37 °C for 1 h. Cells incubated in the absence of drug were used as negative controls. The extracts were evaporated and reconstituted with 100 μL methanol-water (20:80, v/v). The samples were analyzed by the LC–MS/MS method.

2.7. Flow cytometry analysis

Intracellular drug accumulation was investigated using a FACSCanto II Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA), as reported. Briefly, cells (1 × 10⁶ cells per well) were incubated with phenol red-free RPMI 1640 medium containing 10% FBS and 800 nmol/L of mitoxantrone at 37 °C for 1 h. Cells incubated in the absence of drug were used as negative controls. Cells were then washed twice with ice-cold PBS buffer, re-suspended, and subjected to flow cytometry analyses with a 635 nm red diode laser and a 670 nm band pass filter. Drug efflux ability was reflected by the fluorescence of drug accumulated within cells. Flow cytometry data were analyzed by FlowJo software (BD Biosciences). Relative intracellular drug accumulation was calculated by normalized geometric mean of BERA/miR-328-3p group to the control group after subtraction of the basal fluorescence (negative control).

2.8. Mitoxantrone cytotoxicity

Cytotoxicity studies were performed as described previously. In brief, cells were seeded at 5000 cells/well in 96-well plate and cultured overnight. Attached cells were treated with 5 nmol/L of BERA/miR-328-3p or control RNA plus various concentrations of mitoxantrone (0–1000 nmol/L). After 72 h, cell viability was determined using MTT assay. Mitoxantrone chemosensitivity data were fit to a normalized, inhibitory dose-response model with variable slope, \( Y = 100(1+10^{-k})(\log IC_{50} - X) \times \text{Hill slope} \). All experiments were carried out in triplicate and repeated once with separate cultures.

2.9. Statistical analysis

All values were expressed as mean ± SD. Unpaired Student's t-test, one-way or two-way analysis of variance was used to perform statistics analysis. Difference was considered as significant if \( P \) value was less than 0.05.

3. Results

3.1. Expression of BERA/miR-27b-3p and BERA/miR-328-3p in E. coli and purification to a high homogeneity by anion exchange FPLC

The expression of pre-miR-27b-123nt using tRNA scaffold was very low, and thus we employed the tRNA-pre-miR-34a based carrier for the production of miR-27b-3p (Fig. 1A). In particular, we replaced the 22-nt miR-34a-5p with 21-nt miR-27b-3p, as well as their complementary sequences accordingly (Supporting Information Table S1). To assess to what degree target BERA/miR-27b-3p was heterogeneously expressed in bacteria, total RNAs were extracted from HST08 E. coli at 16 h post-transformation with BERA/miR-27b-3p expression plasmid, and then subjected to RNA electrophoresis. As shown in Fig. 1B, a 200 nt RNA band appeared, indicating a successful expression of target BERA/miR-27b-3p. As expected, the level of BERA/miR-27b-3p was much higher than that of tRNA-hsa-miR-27b-3p-123nt (Fig. 1B), supporting the advantages of tRNA/pre-miRNA-based platform in producing target miRNA/siRNA agents.

An anion-exchange FPLC method was utilized to purify the target BERA/miR-27b-3p. Gradient elution with low to high concentration of sodium chloride buffer successfully separated the recombinant BERA/miR-27b-3p, which was eluted at 8.7 min (Fig. 1C), from other small RNAs, tRNAs, and 5S ribosomal RNA using a UNO Q6 column. The purity of isolated recombinant ncRNAs in individual fractions were confirmed by the urea-PAGE analyses (Fig. 1C), and the final BERA/miR-27b-3p showed a high degree of homogeneity (>95%) by HPLC analysis. BERA/miR-328-3p was expressed by using an optimized pre-miR-34a derivative and purified by a streamlined FPLC method, as we reported very recently. As a result, BERA/miR-328-3p accounted for >50% of total bacterial RNAs, and we readily obtained >10 mg of final BERA/miR-328-3p molecule (>98% pure by HPLC) from 1 L bacterial fermentation.

3.2. BERA/miR-27b-3p is processed to mature miRNA in human LS-180 cells and effectively reduces VDR and CYP3A4 expression levels

To assess whether mature miR-27b-3p can be produced from BERA/miR-27b-3p in LS-180 cells, a selective stem-loop RT-qPCR assay was used to quantitate mature miR-27b-3p. The data showed that miR-27b-3p level was 10- to 40-fold higher in LS-180 cells transfected with BERA/miR-27b-3p than control RNA, and the high
levels of mature miR-27b-3p (>20 fold) persisted 96 h post-transfection (Fig. 2A). These results demonstrated that BERA/miR-27b-3p was successfully transfected into LS-180 cells and processed to mature miR-27b-3p.

Our previous studies revealed that the well-conserved miR-27b-3p can regulate CYP3A4 expression in human carcinoma cells via targeting of the 3′-UTR of CYP3A4 and VDR/NR1115. Therefore, we assessed the effectiveness of BERA/miR-27b-3p in the modulation of CYP3A4 expression in LS-180 cells. Firstly, we evaluated whether CYP3A4 was induced in LS-180 cells by 1α-VD3. RT-qPCR analyses (Fig. 2B) using gene-specific primers confirmed that CYP3A4 mRNA levels were increased sharply in cells following the exposure to VD3, whereas there was no difference in VDR mRNA levels between cells treated with VD3 and vehicle control (Fig. 2C). The treatment of BERA/miR-27b-3p led to a modest reduction (20%) of both VDR and CYP3A4 mRNA level, as compared to the control RNA treated LS-180 cells (Fig. 2C). Further immunoblot analyses revealed a 3-fold increase in CYP3A4 protein level in LS-180 cells after VD3 induction (Fig. 2D). Following the transfection of VD3-treated LS-180 cells with BERA/miR-27b-3p, CYP3A4 protein levels were reduced by 30% and VDR levels was suppressed by over 60%, as compared to control RNA treatment (Fig. 2D), indicating the modulation of target ADME gene expression by miR-27b.

3.3. BERA/miR-27b-3p consequently alters the cellular drug metabolism capacity of CYP3A4

Furthermore, we investigated the consequent influence on cellular drug metabolism capacity. MDZ, a widely used CYP3A4 probe substrate36, was utilized to evaluate cellular CYP3A4 enzymatic activity. MDZ and 1′-OH-MDZ, the major metabolite generated by CYP3A437, were quantified by a sensitive and specific LC–MS/MS method35. Our data revealed that the [1′-OH-MDZ]/[MDZ] metabolic ratio after exposure to MDZ for 1.5 h (at 48 h post-transfection), was dramatically increased by 1α-VD3 treatment. 1′-OH-MDZ formation was significantly lower in LS-180 cells treated with BERA/miR-27b-3p than control RNA (E). Values are mean ± SD of triplicate treatments. *P < 0.05; **P < 0.01; ***P < 0.001, compared to vehicle or control RNA group (Student’s t-test).
3.4. BERA/miR-328-3p is processed to target miRNA in human MCF7/MX100 cells and effectively suppresses ABCG2 expression

To examine if BERA/miR-328-3p could be processed to target miR-328-3p in human MCF7/MX100 and BeWo cells, we quantitated mature miR-328-3p using selective stem-loop RT-qPCR assay 48 h post transfection. Our data revealed a 2400-fold higher level of mature miR-328-3p in MCF7/MX100 cells treated with BERA/miR-328-3p than the control RNA. Similarly, BERA/miR328-3p-treated BeWo cells showed 250-fold higher levels of miR-328-3p than those cells treated with RNA control (Fig. 3A). These results demonstrated that BERA/miR-328-3p was successfully transfected into human MCF7/MX100 and BeWo cells and processed to target miR-328-3p.

To evaluate the impact of BERA/miR-328-3p on ABCG2 expression, a validated target for miR-328-3p21,22, qPCR and immunoblot analyses were carried out to examine ABCG2 mRNA and its protein levels using specific primers and antibody, respectively. While low concentrations of control RNA (10 nmol/L) showed no or minimal effects on ABCG2 mRNA or its protein expression, as compared to vehicle control (Fig. 3B and C), BERA/miR-328-3p significantly reduced the levels of ABCG2 mRNA and its protein by approximately 50% and 40%, respectively, in MCF7/MX100 cells as compared to control RNA treatment. Surprisingly, no significant

Figure 3  BERA/miR-328-3p is processed to miR-328-3p in human cancer cells and consequently knocks down ABCG2 levels, leading to higher intracellular accumulation of mitoxantrone and greater sensitivity to mitoxantrone. Human MCF7/MX100 and BeWo cells were transfected with 10 nmol/L BERA/miR-328-3p, control RNA or vehicle for 48 or 72 h. Level of miR-328-3p in BERA/miR-328-3p treated cells was significantly higher than tRNA control (A). (n = 3/group; "*** P < 0.001, "* P < 0.01, compared to the vehicle or tRNA control; one-way ANOVA). As a result, ABCG2 mRNA (B) and protein (C) levels were significantly reduced in BERA/miR-328-3p treated MCF/MX100 cells but not in BeWo cells. ("***P < 0.001, "P < 0.01, compared to the vehicle or control RNA; n = 3 per group; one-way ANOVA). Flow cytometry analyses revealed that compared to the vehicle control, MCF-7/MX100 cells transfected with BERA/miR-328-3p had significantly higher mitoxantrone fluorescence intensity (D). ("P < 0.05, compared to the vehicle control; n = 3/group; one-way ANOVA). BERA/miR-328-3p significantly sensitized MCF7/MX100 cells but not BeWo cells to mitoxantrone. The estimated EC50 and Hill slope for mitoxantrone (MX) cytotoxicity against BERA/miR-328-3p- and control tRNA-treated MCF7/MX100 and BeWo cells ("***P < 0.001, compared to vehicle and control RNA; n = 4/group; one-way ANOVA).
changes in ABCG2 mRNA and its protein expression levels by BERA/miR-328-3p treatment were shown in BeWo cells.

3.5. BERA/miR-328-3p is able to increase the intracellular accumulation of mitoxantrone and enhance the sensitivity of human MCF7/MX100 cells to mitoxantrone

To investigate to what degree drug disposition may be altered in cells with the change of ABCG2 protein expression by BERA/miR-328-3p, we conducted flow cytometry analyses to directly determine intracellular accumulation of mitoxantrone, an ABCG2 substrate anticancer drug. The data showed that, MCF-7/MX100 cells transfected with BERA/miR-328-3p had higher mitoxantrone fluorescence intensity as compared to control RNA and vehicle treated cells (Fig. 3D), despite that it does not reach to statistical significance. By contrast, there was no difference in intracellular mitoxantrone fluorescence between BERA/miR-328-3p-treated BeWo cells and controls, consistent with the finding on an unchanged ABCG2 protein expression (Fig. 3C).

Lastly, we examined if recombinant BERA/miR-328-3p could alter the sensitivity of human carcinoma cells to mitoxantrone. MTT assays were employed to determine the mitoxantrone cytotoxicity against cancer cells after transfection with BERA/miR-328-3p, control RNA, and vehicle. Our data showed that BERA/miR-328-3p transfected MCF7/MX100 cells were more sensitive to mitoxantrone than control RNA and vehicle-treated cells (Fig. 3E). The greater chemosensitivity was also indicated by a significantly lower EC50 value in cells transfected with BERA/miR-328-3p (5.86 nmol/L) than control RNA (166.9 nmol/L) and vehicle control (185.0 nmol/L) (Fig. 3E). In contrast, BERA/miR-328-3p was unable to sensitize BeWo cells to mitoxantrone treatment, which is agreement with the finding on the unchanged ABCG2 protein expression and intracellular drug accumulation (Fig. 2C and D). Together, these findings indicated that modulation of ABCG2 transporter expression with biologic miR-328-3p molecule could facilitate intracellular drug accumulation and thus sensitize the drug-resistant MCF7/MX100 cells to chemotherapy.

4. Discussion

Evidence is emerging that noncoding miRNAs play important roles in the control of drug disposition and response whose research necessitates the development and utilization of proper genetic and pharmacological tools. Chemically engineered miRNA mimics have been predominately utilized for a large number of studies due to the easy accessibility, even though their exact chemical modifications are not disclosed to users and readers, and it remains unknown how excessive artificial modifications will alter the higher-order structures, activities and toxicities of miRNAs. Inspired by protein bioengineering technology that offers large-scale biologic proteins for research and therapy, we have recently established a novel tRNA/pre-miRNA based RNA bioengineering technology for the production of highly-structured, stable natural miRNA reagents with minimal posttranscriptional modifications which was utilized for the production of miR-27b-3p and miR-328-3p in the present study.

Previous studies have demonstrated that miR-27b-3p regulated CYP3A4 expression via direct and indirect targeting, using either plasmid-based miRNA expression materials or early version recombinant miRNA just using tRNA as scaffold. It is also noteworthy, compared to the miR-27-3p agent produced with tRNA carrier, BERA/miR-27-3p made in current study using the novel tRNA/pre-miR-34a based RNA bioengineering platform (Fig. 1) is characterized by a much greater level of expression in E. coli and thus higher overall yield of target BERA/miRNA. As the tRNA/pre-miR-34a carrier is refined further, the BERA/miR-328-3p was produced at surprisingly high levels, i.e., > 50% of total bacterial RNA and > 10 mg of pure BERA/miR-328-3p from 1 L fermentation. These results support the consistent high-yield, large-scale and cost-effective production of biologic RNAi molecules through fermentation using our novel tRNA/pre-miRNA based technology that should be addition to existing tools for RNA research and drug development.

To assess the biological activity of BERA/miR-27b-3p in the regulation of CYP3A4-mediated drug metabolism, CYP3A4 mRNA and its protein levels as well as CYP3A-dependent midazolam 1'-hydroxylation activity were firstly induced by VD3 treatment in human colon carcinoma LS-180 to mimic the physiological transcriptional activation in human enterocyte. BERA/miR-27b-3p was subsequently transfected into LS-180 cells which was indeed processed into high levels of mature miR-27b-3p (Fig. 2). This led to the interference of VDR-CYP3A4 signaling pathway, as manifested by a significant suppression of the mRNA and protein levels of both VDR and CYP3A4. Consequently, BERA/miR-27b-3p treatment caused a reduction of CYP3A4 enzymatic activity, as manifested by midazolam 1'-hydroxylation. By contrast, enzymatic activities of CYP1A2, 2C9, 2D6, and 2E1 measured simultaneously using the cocktail LC–MS/MS method were below the quantification limits, supporting the low or lack of expression of CYP1A2, 2C9, 2D6, and 2E1 in LS-180 cells.

The function of BERA/miR-328-3p in the regulation of ABCG2 and subsequent effects on drug disposition and chemosensitivity were examined. Upon introduction of target miR-328-3p into the cells, ABCG2 mRNA and its protein levels were knocked down in MCF7/MX100 cells (Fig. 3), leading to a higher level of intracellular accumulation of mitoxantrone. In contrast, ABCG2 expression was not modulated by BERA/miR-328-3p in BeWo cell line which is another well-recognized model for the study of ABCG2. The distinct biological effects of miRNA on its target in different type of cells are likely related to cell-specific regulatory elements including target mRNA abundance and ABCG2 protein level was proven to be dramatically higher in MCF7/MX100 cells than in BeWo cells (Supporting Information Fig. S1). Meanwhile, the inability of miR-328-3p to modulate ABCG2 expression in BeWo cells might be attributable to other factors that are more specific and/or important for placental ABCG2 gene regulation, e.g., the hypoxia signaling transcription factors that has been shown to play a critical role in controlling overall placental ABCG2 expression levels. Further investigations are warranted to understand particular cell properties and cellular conditions for microRNA-mediated regulation and the context-dependent post-transcriptional regulatory network. Nevertheless, the successful suppression of ABCG2 by biologic miR-328-3p molecule in ABCG2-mediated drug resistant MCF7/MX100 cells was able to sensitize the cells to chemotherapy (Fig. 3), supporting the notion that intervention of efflux transporters with miRNAs or chemical inhibitors may help to improve the efficacy of chemotherapeutics.

In summary, this study demonstrated a successful production of biologically active miR-27b-3p and miR-328-3p agents using the novel tRNA/pre-miRNA-based RNA bioengineering technology. Our results showed that the BERA/miR-27b-3p was processed to
mature miR-27b-3p in human carcinoma LS-180 cells in a time-dependent manner. Consequently, biologic miR-27b-3p was capable to suppress VDR and CYP3A4 protein expression, leading to a lower cellular drug metabolism capacity. In addition, BERA/miR-328-3p was effective to modulate ABCG2 expression in drug resistant MCF7/MX100 cells, which subsequently sensitized the cells to chemotherapeutic drug. These findings support that bioengineered miRNA agents can be utilized for the study of miRNA functions in regulation of drug metabolism and disposition, and interference of efflux transporter may improve the outcome of chemotherapy.

Acknowledgments

This work was supported in part by the National Institutes of Health [Grant No. R01GM113888 (Aiming Yu), USA]. Xin Li was supported by Visiting Scholar Programs from China Scholarship Council (201608440507, USA) and Guangzhou Medical University, National Natural Science Foundation of China (81603191, China) and Natural Science Foundation of Guangdong Province (2015A030310153, China). Ye Tian was supported by the 3102018y053 from Fundamental Research Funds for the Central Universities (China). The authors appreciate the access to the Flow Cytometry and Molecular Pharmacology Shared Resources funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute (Grant No. P30CA093373, USA).

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.apsb.2018.12.002.

References

1. Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos 1998;26:1217–22.
2. Yu AM, Pan YZ. Noncoding microRNAs: small RNAs play a big role in regulation of ADME?. Acta Pharm Sin B 2012;2:93–101.
3. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41.
4. Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, et al. Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab Dispos 2016;44:343–51.
5. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 2018;19:38–54.
6. Gu X, Xiao Q, Ruan Q, Shu Y, Dongre A, Iyer R, et al. Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines. Acta Pharm Sin B 2018;8:252–60.
7. Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, et al. Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, IncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 2017;7:241–8.
8. Kreek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein El, et al. Combinatorial microRNA target predictions. Nat Gen 2005;37:495–500.
9. Yokoi T, Nakajima M. microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 2013;53:377–400.
10. Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, et al. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos 2013;41:1725–31.
11. Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. MicroRNA pharmacogenetics: posttranscriptional regulation mechanisms behind variable drug disposition and strategy to develop more effective therapy. Drug Metab Dispos 2016;44:308–19.
12. Nakano M, Nakajima M. Current knowledge of microRNA-mediated regulation of drug metabolism in humans. Expert Opin Drug Metab Toxicol 2018;14:493–504.
13. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006;66:9090–8.
14. Chuturgoon AA, Phulukdaree A, Moodley D. Fumonisin B1 modulates expression of cytochrome P450 1B1 in human hepatoma (Hepg2) cells by repressing Mir-27b. Toxicol Lett 2014;227:50–5.
15. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009;37:2112–7.
16. Ekström K, Skiving I, Ovesli ML, Akilul E, Nylén H, Rane A, et al. miRNA-27b levels are associated with CYP3A activity in vitro and in vivo. Pharmaco Res Perspect 2015;3:e00192.
17. Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, Sánchez L, Manciova V, Curtás-Freixes M, et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics 2015;15:288–92.
18. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1–21.
19. Li MM, Wang WP, Wu WJ, Huang M, Yu AM. Rapid production of novel pre-microRNA agent hsa-miR-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos 2014;42:1791–5.
20. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 2009;583:759–66.
21. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009;75:1374–9.
22. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 2011;81:783–92.
23. TO KK, Leung WW, Ng SS. Exploiting a novel mir-519c-HsR-ABCG2 regulatory pathway to overcome chemo-resistance in colorectal cancer. Exp Cell Res 2015;338:222–31.
24. Xiao J, Zhao L, Ma M, Bai X, He M, Yan Y, et al. Mir-181a enhances drug sensitivity in mitoxantrone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 2013;139:717–30.
25. Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, et al. MIR-487a rescensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 2013;339:107–15.
26. Ho PY, Yu AM. Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA 2016;7:186–97.
27. Chen QX, Wang WP, Zeng S, Urayama S, Yu AM. A general approach to high-yield biosynthesis of chimeric miRNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res 2015;43:3587–69.
28. Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, et al. Bioengineered noncoding RNAs selectively change cellular mirnome profiles for cancer therapy. J Pharmacol Exp Ther 2018;365:494–506.
29. Li MM, Addepalii B, Tu MJ, Chen QX, Wang WP, Limbach PA, et al. Chimeric microRNA-1291 biosynthesized efficiently in Escherichia
coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity. Drug Metab Dispos 2015;43:1129–36.

30. Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, et al. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization. J Pharmacol Exp Ther 2015;354:131–41.

31. Li PC, Tu MJ, Ho PY, Jilek JL, Duan Z, Zhang QY, et al. Bioengineered NRF2-siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells. Drug Metab Dispos 2018;46:2–10.

32. Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, et al. Bioengineered ncRNAs selectively change cellular miRNome profiles for cancer therapy. J Pharmacol Exp Ther 2018;354:131–41.

33. Ponchon L, Beauvais G, Nonin-Lecomte S, Dardel F. A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc 2009;4:947–59.

34. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, et al. Transcriptional control of intestinal cytochrome P-4503A by 1α, 25-dihydroxy vitamin D3. Mol Pharmacol 2001;60:1399–406.

35. Jilek JL, Tian Y, Yu AM. Effects of MicroRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice. Drug Metab Dispos 2017;45:512–22.

36. Olsen LR, Gabel-Jensen C, Wubslet SG, Kongstad KT, Janfelt C, Badolo L, et al. Characterization of midazolam metabolism in locusts: the role of a CYP3A4-like enzyme in the formation of 1'-OH and 4'-OH midazolam. Xenobiotica 2016;46:99–107.

37. Pillai VC, Strom SC, Caritis SN, Venkataramanan R. A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC–MS/MS. J Pharm Biomed Anal 2013;74:126–32.

38. Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L. Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Drug Discov Today 2018;23:1733–45.

39. Lauschke VM, Barragan I, Ingelman-Sundberg M. Pharmacoepegnetics and toxicoepigenetics: novel mechanistic insights and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2018;58:161–85.

40. Jackson SM, Manolaridis I, Kowal J, Zhener M, Taylor NML, Bause M, et al. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nat Struct Mol Biol 2018;25:333–40.

41. Evseenko DA, Paxton JW, Keelan JA. ABC drug transporter expression and functional activity in trophoblast-like cells lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol 2006;290:R1357–65.

42. Arvey A, Larsson E, Sander C, Leslie CS, Marks DS. Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol 2010;6:363.

43. Ahadi A, Sablok G, Hutvagner G. miRTar2GO: a novel rule-based model learning method for cell line specific microRNA target prediction that integrates Ago2 CLIP-Seq and validated microRNA-target interaction data. Nucl Acids Res 2017;45:e42.

44. Francois LN, Gorczyca L, Du J, Bircsak KM, Yen E, Wen X, et al. Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling. Placenta 2017;51:57–63.

45. Erhard F, Haas J, Lieber D, Malterer G, Jaskiewicz L, Zavolan M, et al. Widespread context dependency of microRNA-mediated regulation. Genome Res 2014;24:906–19.

46. Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014;20:793–807.